Whether you're pitching your startup in a competition or for capital, here are some expert tips. Getty Images

One of the things our team at EllieGrid is most famous for is pitching. We have pitched our smart pill box in over 20 business plan competitions, on television, radio, and to so many investors that I have lost count. I can't remember what our first pitch was like but I know it has certainly evolved overtime. You could even say that we A/B tested some of our methods.

When you first organize your thoughts, you want to consider the basics, so before I give my advice, consider these tried-and-true tips.

  • Get to the point — say what your company is in the first 10 seconds
  • Know your audience
  • Shorter usually means better
  • Keep numbers to a minimum
  • Have a clear ask

In order to save you a little time, here are some of the of the lessons I learned the hard way to help you perfect your pitch.

Don't pitch. Tell a story.
I am going to let you in on a little secret: most people don't want to hear your pitch, especially if yours is not the first they have heard that day. Put yourself in their shoes, do you really want to listen to someone ramble on about facts and figures? Chances are, no. Instead, tell a story. Use engaging voices and set the scene. Recall your creative writing classes from high school and how you should mention what it was like in terms of feel, smell, taste, etc. and don't use generic adjectives such as "too small" or "the old way was hard."

People remember how you made them feel
What is in it for your audience? Is it wealth, power, fame, praise or glory, and/or pleasure? It might sound obvious to make this point when pitching, but I suggest you write out your pitch and highlight exactly where you say what is in it for them, maybe even more than once. Making the audience feel like you are caring about their desires and engaging them in conversation will help you be more memorable.

Come full circle
My favorite technique in any pitch or speech is if the speaker can connect the closing back to something they said at the beginning of their pitch. I enjoy this because sometimes the speaker will leave a question unanswered and then reveal how their solution is the answer in a creative way. This keeps your listeners engaged and connects the pain to your solution. Watch a few TED talks and you will see what I mean.

Pitch to a kid
This is probably the best advice I can give because it is a surefire way to make sure your pitch makes sense to a wide range of listeners. This also forces you to leave out jargon and filler words that you think might make you sound fancy like "innovative" or "disruptive" but actually make you sound like everyone else.

------

Regina Vatterott is the COO and co-founder of Ellie Grid, a Houston-based company reinventing medical devices. Read more about Regina here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."